Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer

Bibliography

• Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997;15:3266-74
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20
   PubMed Web of Science ®Google Scholar
• PROVENGE significantly prolongs survival in men with advanced prostate cancer in pivotal Phase 3 IMPACT study. Available from: http://investor.dendreon.com/ReleaseDetail.cfm?ReleaseID = 376922&Header = News [Accessed April 2009]
   Google Scholar
• Coffey DS, Isaacs JT. Prostate tumor biology and cell kinetics: theory. Urology 1981;17:40-53
   PubMed Web of Science ®Google Scholar
• Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238-44
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Barrette TR, Rubin MA, et al. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 2002;62:4427-33
   PubMed Web of Science ®Google Scholar
• Fong L, Small EJ. Immunotherapy for prostate cancer. Semin Oncol 2003;30:649-58
   PubMed Web of Science ®Google Scholar
• Chakraborty NG, Stevens RL, Mehrotra S, et al. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother 2003;52:497-505
   PubMed Web of Science ®Google Scholar
• Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23
   PubMed Web of Science ®Google Scholar
• Madan RA, Gulley JL, Arlen PM. PSA-based vaccines for the treatment of prostate cancer. Expert Rev Vaccines 2006;5:199-209
   PubMed Web of Science ®Google Scholar
• Veeramani S, Yuan TC, Chen SJ, et al. Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr Relat Cancer 2005;12:805-22
   PubMed Web of Science ®Google Scholar
• Vihko P, Virkkunen P, Henttu P, et al. Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase. FEBS Lett 1988;236:275-81
   PubMed Web of Science ®Google Scholar
• Murphy GP, Elgamal AA, Su SL, et al. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998;83:2259-69
   PubMed Web of Science ®Google Scholar
• Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48:326-34
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11:3353-62
   PubMed Web of Science ®Google Scholar
• Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 2008;14:3536-44
   PubMed Web of Science ®Google Scholar
• Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol Ther 2004;4:575-88
   PubMed Web of Science ®Google Scholar
• Kass E, Schlom J, Thompson J, et al. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 1999;59:676-83
   PubMed Web of Science ®Google Scholar
• Kantor J, Abrams S, Irvine K, et al. Specific immunotherapy using a recombinant vaccinia virus expressing human carcinoembryonic antigen. Ann NY Acad Sci 1993;690:370-3
   PubMed Web of Science ®Google Scholar
• Hodge JW, Grosenbach DW, Rad AN, et al. Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. Vaccine 2001;19:3552-67
   PubMed Web of Science ®Google Scholar
• Zhu M, Terasawa H, Gulley J, et al. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res 2001;61:3725-34
   PubMed Web of Science ®Google Scholar
• Palena C, Zhu M, Schlom J, Tsang KY. Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells. Blood 2004;104:192-9
   PubMed Web of Science ®Google Scholar
• Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75
   PubMed Web of Science ®Google Scholar
• Parker KC, Shields M, DiBrino M, et al. Peptide binding to MHC class I molecules: implications for antigenic peptide prediction. Immunol Res 1995;14:34-57
   PubMed Web of Science ®Google Scholar
• Collins EJ, Frelinger JA. Altered peptide ligand design: altering immune responses to class I MHC/peptide complexes. Immunol Rev 1998;163:151-60
   PubMed Web of Science ®Google Scholar
• Correale P, Walmsley K, Nieroda C, et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 1997;89:293-300
   PubMed Web of Science ®Google Scholar
• Correale P, Walmsley K, Zaremba S, et al. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol 1998;161:3186-94
   PubMed Web of Science ®Google Scholar
• Wingren AG, Parra E, Varga M, et al. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol 1995;15:235-53
   PubMed Web of Science ®Google Scholar
• Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 2002;62:5770-7
   PubMed Web of Science ®Google Scholar
• Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 2001;61:4497-505
   PubMed Web of Science ®Google Scholar
• Hodge JW, Sabzevari H, Yafal AG, et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999;59:5800-7
   PubMed Web of Science ®Google Scholar
• Oh S, Hodge JW, Ahlers JD, et al. Selective induction of high avidity CTL by altering the balance of signals from APC. J Immunol 2003;170:2523-30
   PubMed Web of Science ®Google Scholar
• Hodge JW, Chakraborty M, Kudo-Saito C, et al. Multiple costimulatory modalities enhance CTL avidity. J Immunol 2005;174:5994-6004
   PubMed Web of Science ®Google Scholar
• Yang S, Tsang KY, Schlom J. Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells. Clin Cancer Res 2005;11:5603-15
   PubMed Web of Science ®Google Scholar
• Yang S, Hodge JW, Grosenbach DW, Schlom J. Vaccines with enhanced costimulation maintain high avidity memory CTL. J Immunol 2005;175:3715-23
   PubMed Web of Science ®Google Scholar
• Disis ML, Bernhard H, Shiota FM, et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996;88:202-10
   PubMed Web of Science ®Google Scholar
• Gulley J, Chen AP, Dahut W, et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002;53:109-17
   PubMed Web of Science ®Google Scholar
• Etlinger HM, Altenburger W. Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus. Vaccine 1991;9:470-2
   PubMed Web of Science ®Google Scholar
• Kundig TM, Kalberer CP, Hengartner H, Zinkernagel RM. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 1993;11:1154-8
   PubMed Web of Science ®Google Scholar
• Konishi E, Pincus S, Paoletti E, et al. Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens. Vaccine 1994;12:633-8
   PubMed Web of Science ®Google Scholar
• Hodge JW, McLaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 1997;15:759-68
   PubMed Web of Science ®Google Scholar
• Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18:3964-73
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22:2122-32
   PubMed Web of Science ®Google Scholar
• Kaufman H, Wang W, Manola J, DiPaola R. Phase II prime/boost vaccination using poxviruses expressing PSA in hormone-dependent prostate cancer: follow-up clinical results from ECOG 7897 [abstract]. J Clin Oncol 2005;23(16S):4501
   Web of Science ®Google Scholar
• Arlen PM, Skarupa L, Pazdur M, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 2007;178:1515-20
   PubMed Web of Science ®Google Scholar
• DiPaola R, Chen Y, Bubley G, et al. A Phase II study of PROSTVAC-V (vaccinia)/TRICOM and PROSTVAC-F (fowlpox)/TRICOM with GM-CSF in patients with PSA progression after local therapy for prostate cancer: results of ECOG 9802 [abstract]. ASCO Genitourinary Cancers Symposium 2009;110
   Google Scholar
• Kantoff P, Glode L, Tannenbaum S, Bilhartz D. Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients with hormone-refractory prostate cancer [abstract]. J Clin Oncol 2005;24(18S):2501
   Google Scholar
• Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Cellular, Tissue and Gene Therapies Advisory Committee: Sipuleucel-T Briefing Document. Dendreon Corporation. Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4291B1_01.pdf [Accessed February 2009]
   Google Scholar
• Madan R, Gulley J, Dahut W, et al. Overall survival (OS) analysis of a Phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC): implications for clinical trial design [abstract]. J Clin Oncol 2008;16(20S):3005
   Google Scholar
• Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232-7
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170:6338-47
   PubMed Web of Science ®Google Scholar
• Garnett CT, Palena C, Chakraborty M, et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985-94
   PubMed Web of Science ®Google Scholar
• Hodge JW, Guha C, Neefjes J, Gulley JL. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) 2008;22:1064-70; discussion 75, 80-1, 84
   PubMed Web of Science ®Google Scholar
• Ferrara TA, Hodge JW, Gulley JL. Combining radiation and immunotherapy for synergistic antitumor therapy. Curr Opin Mol Ther 2009;11:37-42
   PubMed Web of Science ®Google Scholar
• Sheard MA, Vojtesek B, Janakova L, et al. Up-regulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation. Int J Cancer 1997;73:757-62
   PubMed Web of Science ®Google Scholar
• Quarmby S, Hunter RD, Kumar S. Irradiation induced expression of CD31, ICAM-1 and VCAM-1 in human microvascular endothelial cells. Anticancer Res 2000;20:3375-81
   PubMed Web of Science ®Google Scholar
• Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002;8:1765-80
   PubMed Web of Science ®Google Scholar
• Lechleider RJ, Arlen PM, Tsang KY, et al. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 2008;14:5284-91
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Abrams S, Coleman C, et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004;64:4328-37
   PubMed Web of Science ®Google Scholar
• Kudo-Saito C, Schlom J, Camphausen K, et al. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res 2005;11:4533-44
   PubMed Web of Science ®Google Scholar
• Clinical Trials (PDQ): Samarium Sm 153 Lexidronam Pentasodium With or Without Vaccine Therapy and GM-CSF in Treating Patients With Prostate Cancer and Bone Metastases. Available from: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid = 535561&version = patient&protocolsearchid = 4937826 [Accessed February 2009]
   Google Scholar
• Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007;12:4957-71
   PubMed Web of Science ®Google Scholar
• Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 2001;98:14565-70
   PubMed Web of Science ®Google Scholar
• Matejuk A, Hopke C, Vandenbark AA, et al. Middle-age male mice have increased severity of experimental autoimmune encephalomyelitis and are unresponsive to testosterone therapy. J Immunol 2005;174:2387-95
   PubMed Web of Science ®Google Scholar
• Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005;7:239-49
   PubMed Web of Science ®Google Scholar
• Sutherland JS, Goldberg GL, Hammett MV, et al. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 2005;175:2741-53
   PubMed Web of Science ®Google Scholar
• Goldberg GL, Sutherland JS, Hammet MV, et al. Sex steroid ablation enhances lymphoid recovery following autologous hematopoietic stem cell transplantation. Transplantation 2005;80:1604-13
   PubMed Web of Science ®Google Scholar
• Arlen PM, Gulley JL, Todd N, et al. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol 2005;174:539-46
   PubMed Web of Science ®Google Scholar
• Madan RA, Gulley JL, Schlom J, et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res 2008;14:4526-31
   PubMed Web of Science ®Google Scholar
• Clinical Trials (PDQ): Flutamide With or Without Vaccine Therapy in Treating Patients With Nonmetastatic Prostate Cancer. Available from: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid = 535593&version = patient&protocolsearchid = 4937826 [Accessed February 2009]
   Google Scholar
• Abdalla EE, Blair GE, Jones RA, et al. Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line. J Natl Cancer Inst 1995;87:489-96
   PubMed Web of Science ®Google Scholar
• Fisk B, Ioannides CG. Increased sensitivity of adriamycin-selected tumor lines to CTL-mediated lysis results in enhanced drug sensitivity. Cancer Res 1998;58:4790-3
   PubMed Web of Science ®Google Scholar
• Aquino A, Prete SP, Greiner JW, et al. Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells. Clin Cancer Res 1998;4:2473-81
   PubMed Web of Science ®Google Scholar
• Matsuzaki I, Suzuki H, Kitamura M, et al. Cisplatin induces fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells. Oncology 2000;59:336-43
   PubMed Web of Science ®Google Scholar
• Chan OT, Yang LX. The immunological effects of taxanes. Cancer Immunol Immunother 2000;49:181-5
   PubMed Web of Science ®Google Scholar
• Arlen PM, Gulley JL, Parker C, et al. A randomized Phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006;12:1260-9
   PubMed Web of Science ®Google Scholar
• Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459-65
   PubMed Web of Science ®Google Scholar
• Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3:611-8
   PubMed Web of Science ®Google Scholar
• Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270:985-8
   PubMed Web of Science ®Google Scholar
• Gerritsen W, Van Den Eertwegh A, De Gruijl T, et al. A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with fully human anti-CTL4 antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC) [abstract]. ASCO Prostate Cancer Symposium 2007;262
   Google Scholar
• Gerritsen W, van den Eertwegh A, De Gruijl T, et al. Expanded Phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC) [abstract]. J Clin Oncol 2008;26(Suppl):5146
   Google Scholar
• Mohebtash M, Madan R, Arlen P, et al. Phase I trial of targeted therapy with PSA-TRICOM vaccine and ipilimumab in patients with metastatic castration-resistant prostate cancer [abstract]. ASCO Genitourinary Cancers Symposium, 26 February 2009, Orlando, Florida 2009;184
   Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
   PubMed Web of Science ®Google Scholar
• Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007;13:3776-82
   PubMed Web of Science ®Google Scholar
• Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factor: secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007;13:3883-91
   PubMed Web of Science ®Google Scholar
• Rini BI. Technology evaluation: APC-8015, Dendreon. Curr Opin Mol Ther 2002;4:76-9
   PubMed Web of Science ®Google Scholar
• Patel PH, Kockler DR. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother 2008;42:91-8
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64
   PubMed Web of Science ®Google Scholar
• Morse MA, Clay TM, Mosca P, Lyerly HK. Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther 2002;2:827-34
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455-8
   PubMed Web of Science ®Google Scholar
• Piccirillo CA, Shevach EM. Cutting edge: control of CD8 + T cell activation by CD4 + CD25 + immunoregulatory cells. J Immunol 2001;167:1137-40
   PubMed Web of Science ®Google Scholar
• Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-6
   PubMed Web of Science ®Google Scholar
• Fu T, Shen Y, Fujimoto S. Tumor-specific CD4( + ) suppressor T-cell clone capable of inhibiting rejection of syngeneic sarcoma in A/J mice. Int J Cancer 2000;87:680-7
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4 + CD25 + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-44
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8 + tumor-infiltrating lymphocytes and a high CD8 + /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102:18538-43
   PubMed Web of Science ®Google Scholar
• Kawaida H, Kono K, Takahashi A, et al. Distribution of CD4 + CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J Surg Res 2005;124:151-7
   PubMed Web of Science ®Google Scholar
• Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4( + )CD25( + ) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-72
   PubMed Web of Science ®Google Scholar
• Tanaka H, Tanaka J, Kjaergaard J, Shu S. Depletion of CD4 + CD25 + regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 2002;25:207-17
   PubMed Web of Science ®Google Scholar
• Jones E, Dahm-Vicker M, Simon AK, et al. Depletion of CD25 + regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002;2:1
   PubMedGoogle Scholar
• Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4( + )25 + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-8
   PubMed Web of Science ®Google Scholar
• Motoyoshi Y, Kaminoda K, Saitoh O, et al. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep 2006;16:141-6
   PubMed Web of Science ®Google Scholar
• Cumashi A, Tinari N, Rossi C, et al. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 2008;270:229-33
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Hutson TE, Berry WR, et al. Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. Clin Genitourin Cancer 2008;6:134-7
   PubMed Web of Science ®Google Scholar
• Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-82
   PubMed Web of Science ®Google Scholar